PRTODAY / NewswireToday Free press release distribution service network

Written by / Agency / Source: KDM Communications Ltd

Check Ads Availability|e-mail Article

Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

Leica Microsystems Releases Fully Automated HER2 FISH Test - Leica Microsystems releases fully automated HER2 FISH test -
Leica Microsystems Releases Fully Automated HER2 FISH Test


NewswireToday - /newswire/ - St Neots, Cambridgeshire, United Kingdom, 2011/04/13 - Leica Microsystems releases fully automated HER2 FISH test -

Your Banner Ad Here instead - Showing along with ALL Articles covering Medical Services/Equipment Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


Leica Microsystems has announced the European release of the fully automated Leica HER2 FISH System for the Leica BOND advanced staining system. Designed for easy and accurate assessment of HER2 gene status in breast cancer tissue, the Leica HER2 FISH System combines the use of the gold standard PathVysion®* HER2 FISH probes, supplied by Abbott Molecular Inc, with Leica’s industry-leading BOND automated platform, delivering accurate results for diagnostic confidence.

Automation of labor intensive FISH techniques reduces process variation while offering walk-away convenience. Samples can be processed continuously, eliminating the need to batch cases, offering fast turnaround times, saving valuable hands-on time and allowing rapid reporting of patient results. This fully automated system uses an optimized ready-to-use Leica HER2 FISH reagent kit with a robust BOND protocol to produce consistent, high quality stained slides. The system enhances the laboratory workflow, increasing efficiency and enabling the laboratory to provide a responsive service to their clinicians and clients.

Arnd Kaldowski, President of Leica Biosystems, commented: “Our HER2 FISH test provides improved workflow for the laboratory while maintaining the highest standard associated with HER2 FISH testing. Leica BOND users are now able to perform a full compliment of IHC and ISH breast testing on our BOND system, offered through our Theranostics and Novocastra™ product lines, delivering the diagnostic confidence needed for effective patient management.”

Leica Microsystems is a world leader in microscopes and scientific instruments. Founded as a family business in the nineteenth century, the company’s history was marked by unparalleled innovation on its way to becoming a global enterprise. Its historically close cooperation with the scientific community is the key to Leica Microsystems’ tradition of innovation, which draws on users’ ideas and creates solutions tailored to their requirements. At the global level, Leica Microsystems is organized in four divisions, all of which are among the leaders in their respective fields: the Life Science Division, Industry Division, Biosystems Division and Medical Division.

Leica Microsystems' Biosystems Division, also known as Leica Biosystems, offers histopathology laboratories the most extensive product range with appropriate products for each work step in histology and for a high level of productivity in the working processes of the entire laboratory.

Leica Microsystems is represented in over 100 countries with 12 manufacturing facilities in 7 countries, sales and service organizations in 19 countries and an international network of dealers. The company is headquartered in Wetzlar, Germany.

Intended Use
The Leica HER2 FISH System ( is designed to detect amplification of the HER2/neu gene via fluorescence in situ hybridization (FISH) in formalin-fixed, paraffin-embedded human breast cancer tissue specimens. The Leica HER2 FISH System is indicated as an aid in the assessment of patients for whom Herceptin®** (trastuzumab) treatment is being considered (see Herceptin package insert).

The Leica HER2 FISH System is not intended for use to screen for or diagnose breast cancer. All other available clinical information should also be taken into consideration, such as tumor size, number of involved lymph nodes, and steroid receptor status. No treatment decision for breast cancer patients should be based on HER2 gene amplification status alone.

Note: All of the patients in the Herceptin clinical trials were selected using an investigational immunocytochemical Clinical Trial Assay (CTA). None of the patients in those trials were selected using the Leica HER2 FISH System. The Leica HER2 FISH System has been compared to the Abbott Molecular PathVysion® HER2 DNA Probe Kit assay on an independent set of samples and found to provide acceptably concordant results. The actual correlation of the results of the Leica HER2 FISH System to clinical outcome has not been established.

*PathVysion® is a trademark of Abbott Molecular Inc. All Rights Reserved. Used under License.
**Herceptin® is a trademark of Genentech, Inc. and F. Hoffmann-La Roche Ltd.

Your Banner Ad Here instead - Showing along with ALL Articles covering Medical Services/Equipment Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


Written by / Agency / Source: KDM Communications Ltd


Availability: All Regions (Including Int'l)


Traffic Booster: [/] Quick Newswire Today Visibility Checker


Distribution / Indexing: [+]

# # #
  Your Banner Ad showing on ALL
Medical Services/Equipment articles,
CATCH Visitors via Your Competitors Announcements!

Leica Microsystems Releases Fully Automated HER2 FISH Test

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name Newswire Today and LINK as the source.
  Is this your article?
Activate ALL web links and social stream by Upgrading to Press Release PREMIUM Plan Now!

Publisher Contact: Sarah Khan - 
+44(0)14 8040 5333 ideas[.]
Newswire Today - PRZOOM / PRTODAY disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any KDM Communications Ltd securities in any jurisdiction including any other companies listed or named in this release.

Medical Services/Equipment via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY

Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

Read Latest Articles From KDM Communications Ltd / Company Profile

Read Medical Services/Equipment Most Recent Related Newswires:

Agfa Specialty Products Announces the Launch of UNIQOAT
Sparta Releases Stratas 3.0 and TrackWise Intake
GE Healthcare Signs Agreement with HealthTrust to Supply Radiopharmaceuticals
GE Introduces CardioGraphe - The World’s First Dedicated Cardiovascular CT System
Frost & Sullivan Lauds ClearFlow’s ACT® Technology as a Transformational Force in Post-operative Cardiothoracic Surgery Protocols
ZOLL Receives Health Canada Approval for Two New Models of AEDS
ZOLL Hospital Wearable Defibrillator Receives Premarket Approval from the FDA
AFC Industries Joins HIMSS for its 56th Edition
Medical Companies Flock to Israel for R&D Support Infrastructure and Inorganic Growth Opportunities Finds Frost & Sullivan
GE Healthcare Expands MRI Contrast Media Product Range in Europe with Launch of Macrocyclic Agent Clariscan
Sparta Systems Launches Product Registration Tracking for 123Compliance Cloud QMS
Frost & Sullivan Lauds SnooZeal’s Unique Electrical Stimulation Therapy for Sleep Apnea in the European Market
ZOLL Expands the Rescuer Experience at EMS Today
Traditional Mass Spectrometers Give Way to High-resolution Technologies Such as MALDI-TOF Finds Frost & Sullivan
AccuVein, Inc. Named A Best Place to Work in Medical Sales for Second Consecutive Year

Boost Your Social Network
& Crowdfunding Campaigns

NewswireToday Celebrates 10 Years in Business



Visit  La Bella Bakery Artisan Bakery Arizona

  ©2017 Newswire Today — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR free press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution freenewswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
PRTODAY & NewswireTODAY are NOT affiliated with USA TODAY (